The cell is a complex system involving numerous components, which may often interact in a nonlinear dynamic manner. Diseases at the cellular level are thus likely to involve multiple cellular constituents and pathways. As drugs, or drug combinations, may act synergistically on these multiple pathways, they might be more effective than their respective single target agents.
Introduction
The perturbation of cell homeostasis due to genetic and/or epigenetic changes can result in aberrant proteins or cell organelles. These can lead to uncontrolled cell growth, providing the underlying basis for most morbid and mortal illnesses. Modern drug discovery mainly aims to identify novel drug molecules which directly bind and inhibit such aberrant molecular cell targets 1, 2 . One of the main challenges of drug discovery, therefore, is to identify such drug targets in a complex cellular system.
Biological systems, on a cellular, organ or body level, can be considered as complex systems 3 .
Complex biological systems, however, are very different from other types of systems, such as an engineering system. A complex system consists of a large number of building blocks, e.g.
proteins, mRNA, organelles. In biological systems, some of these functional molecules are selforganized into pathways 4, 5 . In contrast, engineering systems are assembled with parts that are manufactured by following the first principle 6 . The system's functionality is well defined according to the design goal. On the other hand, cellular system level response emerge from a network of regulatory and signaling pathways and are adaptive with a large dynamic range 7 .
Obviously, sorting out an aberrant cellular component for drug targeting in the midst of a complex system is like finding a needle in a haystack. Even if a target is identified and a drug is developed to inhibit it, single drug treatment often leads to drug resistance 8, 9 . Furthermore, in many diseases it is common for there to be more than one disease causing target due to non-linear interactions between signaling pathways. Therefore, combinations of synergetic drugs targeted to several pathways and administered at low dose could represent an efficacious treatment strategy 10, 11 .
The efficacy of a drug combination not only depends on the selection of the drugs, but also on the dose ratios among the drugs 10 . M drugs with N dose levels will generate N M possible combinations. A brute force search for an optimal drug combination in such a large parameter space is a prohibitive task. The recently developed Feedback System Control (FSC) technique 12 can direct biosystems toward a desired phenotypic outcome based on combinatorial drug stimulation. FSC can home in an optimal drug combination with several orders of magnitude less experimental efforts than testing all of the N M possibilities. FSC takes a top-down systems approach by focusing on improving a phenotype based on varying the combinatorial input stimuli.
This method completely avoids the bottom-up approach frequently used in biology, where one attempts to predict and control cell behavior based on an understanding how different signaling pathways and molecules interact. It is surprising that typically less than 15 iteration loop tests can identify the optimal combination from millions or more alternatives. FSC is a platform technology which has been demonstrated in the treatment of cancers 13 , inhibition of viral infection 10 , the maintenance of human embryonic stem cells (hESC) 11 , the reformulation of Chinese herbal medicine 14 , and the differentiation of mesenchymal stem cells 15 .
Even though it took a long time and a lot of effort, many new targeted drugs and their combinations have been introduced to the clinics in the past three decades. Unfortunately, patients' response rates to most targeted drugs remain fairly low in cancer treatments. For example, the response rate for lung cancer patients is about 25% and only 10% for hepatoma 16 .
Many reasons contribute to these unsatisfactory results. Patient diversity and cancer heterogeneity are among some of the factors which influence the efficacy cancer therapy 17 . Genetic profiles of individual patients with the same disease vary across genders, races, etc. and causes diversities of proteomic network through transduction. The current clinical practice for chemotherapy is to use the same regimen for the patients with the same type of disease 18, 19 , therefore, relatively low response rates are frequently observed.
With the rapid development of micro/nano technology based diagnostic instrument, fast and affordable genetic analyses have become available and this has enabled the development of genotypic personalized medicine (GPM) 20, 21 . GPM is based on the principle of customizing single targeted or combinatorial drugs for a group of patients with similar gene profiles and can result in better therapeutic outcomes. These strategies, however, disregard the fact that disease can also be independently caused by epigenetic stimulations 22, 23 . Therapeutic procedures can obviously be much more precise, if they include the consideration of disease phenotypes. However, phenotypic personalized medicine (PPM) needs to have quantitative efficacy-drug relationship a priori.
In this paper, we will present the results from investigations on four biological models, including non-small-cell lung cancer (NSCLC) treatment, Herpes Simplex Virus type 1 (HSV-1)
eradication, mesenchymal stem cell osteogenesis induction and cancer angiogenesis inhibition. In these studies, we show that the efficacy-drug dose relationships of each system are simple and smooth. This finding comes from one of the fundamental characteristics of complex system. Due to the process of evolution, organisms have developed in such a way that they are robust and adaptive to environmental stimulations. That is, the bio complex system response surface to extracellular stimulations must be very smooth. This is the reason why we can easily locate an optimal drug combination in a biological system after approximately 15 iterations of the FSC technique. By testing a small group of subjects, the efficacy-drug surface can be established. With this quantitatively defined relationship, PPM can be practiced with great confidence.
Results

Non-Small-Cell Lung Cancer (NSCLC) reduction
The authors of this study 13 We then further analyzed the 512 data points by building a second order linear regression model. At first we looked at the impact of the dose change of each individual drug on the therapeutic output 'y' which quantifies cancer cell survival. These single drug effects, also known as 'main effects' in statistics are shown in Fig. 1 . All three drugs demonstrate significant main effects, as can be seen by the obvious decrease of 'y' with increasing dose of each compound. to re-examine the data using another modeling strategy. In this case however, the residual points fall close to a straight line, suggesting that the assumption of a normal distribution holds. Only a few points fall far from the straight line. These few points are unlikely to significantly influence the overall statistical analysis and can be treated as statistical outliers. In order to tell which data points are likely to be outliers (e.g. points that are due to errors in the experimental measurements), we generated the Cook's distance for each data point as shown in Fig. 2d . Cook's distance is a well-accepted way to tell whether any outliers exist in the data set. Data point No.
337 clearly shows a Cook's distance value larger than any other data point. This indicates that this particular point should be analyzed carefully and possibly repeated, as it is likely that a measurement or recording error occurred. One key characteristic of linear regression modeling, especially lower order regression models is that the response surfaces can be depicted with smooth contours, at least in the region of the experimental values reported. In Fig. 3 , contour plots of each of the two-drug pairs out of the three drugs tested are generated while fixing the third drug's dose to be equal to zero. Thus when I-3'-M is not added to the mixture, AG490 and U0126 combined optimally when AG490's dose is between 200 and 250 µM, while U0126's dose is between 80 and 100 µM, possibly indicating some degree of synergism. On the other hand, when the concentration U0126 is set to zero, and AG490 and I-3'-M are applied together, the optimal anti-cancer effect is obtained when both drugs are at the high dose end, i.e. no synergy is observed between these two drugs. Finally, when the concentration of AG490 is set to zero, and we look at U0126 and I-3'-M being used together, the optimal anti-cancer effect occurs when the U0126 concentration is between 100 and 150 µM, and either higher or lower doses of this compound lead to a less optimal readout. The three contour plots generated all appear to be quite smooth in the domain of concentrations tested, confirming that the relation between the three chosen anti-cancer drugs can be expressed with a simple second order linear regression model.
Herpes Simplex Virus type 1 (HSV-1) infection
In the first example above, we examined a typical anti-cancer system treated with combinations of three drugs. In this second example we investigate viral infection, another kind of complex biological system which is commonly treated with a drug mixture. In these viral-based diseases the drugs can interact with both the host cells and the virus itself, thus increasing the complexity of the system. We were now interested to see if in such a complex biological system the relation agree quite well with one another. As in the case of NSCLC above, we also examined the residual plot and the Normal Q-Q plot for this model. These data are shown in Fig. 5b and 5c, and showed no clear indications suggesting failure or bias of the model. The Cook's distance plot suggested only a few outliers, as can be seen in Fig. 5d . Therefore one may conclude that even in such a complex case as viral infection, the effect of a drug mixture on the percentage of viral infected cells can still be modeled with a 2 nd order linear regression, though with somewhat reduced confidence.
Mesenchymal Stem cell osteogenesis induction
As a third example of a biologically complex system to optimize drug mixtures for, we chose to In the present study, we further analyzed the same data set as was generated by the FSC search by applying second order linear regression analysis. As in the previous cases, we first looked at the influence of each individual drug on the output 'y'. This is shown in Fig. 6 . It is interesting to note We then repeated the whole analysis by removing data point No. 45. Indeed, the experimental observations and the model predictions basically agree with one another, as can be seen from Fig.   7a . Furthermore, upon examination of the residual plots and the Normal Q-Q plots (shown in Fig.   7b and 7c), we did not observe a clear residual distribution, indicating that even though there was only a modest fidelity, the second order linear regression model was an acceptable approximation to the experimental data. Fig. 7d shows that Cook's distance analysis did not indicate any new outliers either.
Cancer angiogenesis inhibition
After examining the input-output relation for the efficacy of multiple drug treatments in vitro in the three different complex biological systems described above, we found that the system's response can in each case be fairly well modeled with a smooth second order equation. If this finding would be universally true for other complex biological systems, it may be possible to identify optimal drug combinations by testing a limited number of data points, which are then fitted with a second order response function. This function can then be used to identify the optimal drug combination.
In order to test this rather bold hypothesis, we tried to find an optimal combination of a fairly small number of anti-angiogenic drugs (if possible 4 or less), starting from 9 such substances. The starting compounds were carefully selected for their known or presumed complementary antiangiogenic activity. The drugs chosen were: Anginex (1), Avastin (2), Axitinib (3), Erlotinib (4), Anti-HMGB1 antibody (5), Sunitinib (6), Anti-Vimentin antibody (7), RAPTA-C (8), and BEZ-235 (9). As, up to this date, such treatments have been only partially successful with the single components listed above, it is now hoped that by using the FSC technique an effective angiostatic combination of some of the above listed drugs might be found. If, furthermore, this combination would benefit from a significant degree of synergism, it cannot be excluded that the treatment would also imply the use of much lower drug doses than are normally applied with the single compounds. Reduced drug doses may also carry the potential for having fewer side effects and reduced driving force for the development of drug resistant. Four drug concentrations were assigned to each of the 9 starting compounds thus creating 4 9 = 262144 possible drug combinations (Table 1) .
Immortalized human macrovascular endothelial cells (ECRF24) were used in this study. We first applied the FSC technique to optimize these nine drugs over ten iterations. The FSC search optimization will be published in a separate paper as the present article focuses mainly on the analysis of the cell survival response to the different drug doses. In each of the 10 iteration steps, 19 drug combinations were tested, giving a total of 190 data points. Like before we used these points to build a second order linear regression model. As expected, the predictions from the regression model and the data points showed a high correlation of 0.8642. The R 2 value equals 0.7468.
Based on the regression model shown in equation (1) contribution to lowering endothelial cell viability, and thus a higher angiostatic effect. Anginex (1) showed a relatively low single drug effect (β 1 ) but a much higher 2 nd order effect (β 11 ), meaning
Anginex (1) is not likely to be a highly effective drug when used individually. Furthermore, Anginex (1) did not show the desired very low values in Fig. 8a for the interaction with the other drugs. This observation may be interpreted as minimal 'synergies' between Anginex and the other drugs (i.e. large negative values of β 1k ). Based on these reasons, we could confidently drop Anginex (1) from the drug mixture. Moreover, Avastin (2) and Sunitinib (6) did have slightly positive coefficients (β 2 and β 6 ) in Fig. 8a (although this may not be statistically very significant), which is indicative of not very good single drug contributions to the angiostatic effect. As the model is run with real concentrations of each drug, single drug effects are quite important. We therefore dropped drugs (2) and (6). The Anti-HMGB1 Antibody (5) has a quite negative coefficient for its single drug effect (β 5 ). However, unfortunately this drug showed mainly 'antagonistic-like' effects (the β 5k coefficients are largely positive or around zero in Fig. 8a with other drugs), and it had a rather positive value quadratic term (β 55 ). Therefore, drug (5) was also dropped from the drug combination. Finally, the Anti-vimentin Antibody (7) also shows a good single drug effect, but a fairly positive 2 nd order effect, as well as mainly small coefficients for the interactions with other drugs, indicating slight 'synergism' or slight 'antagonism'. We therefore also dropped drug (7) at this point. These procedures lead us to the optimal combination including the following four drugs: Axitinib (3), Erlotinib (4), RAPTA-C (8) and BEZ-235 (9) . In later analysis, axitinib was further eliminated from this mixture, for various reasons including toxicity.
Thus the final optimal drug combination consisted of drug (4) (1uM) + (8) (100uM) + (9) (0.02uM). This combination, at these rather low concentrations was sufficiently potent to inhibit more than 90% of the endothelial cell proliferation. Note that the EC50 values (the values that gave 50% survival) of drug (4), (8), (9) 
Discussion
The diseased state in a cell commonly involves a number of abnormal signaling pathways. It is therefore unlikely that a single drug could inhibit all of the aberrantly activated pathways involved in a disease and its progression. Although in some cases, individual drugs can show satisfying efficacy in the treatment of a disease, the toxicity induced when drugs are used at high dose, and drug resistance accumulated from long-term drug administration, still often limit single-drug regimens as an effective long-term treatment option. An alternative approach is to use drug combinations that can simultaneously target multiple diseased cellular nodes. The synergy among drugs in an effective combination can lead to reduced dose, relieved side-effects and increased efficacy. In all the cases we studied, optimized drug combinations were superior to their singledrug counterparts.
The FSC approach usually identifies the optimal drug combination in less than 15 rounds of experimental efforts, by testing only 2% or less of the total possible search space. This paper, by investigating four different biological systems, demonstrates that although biological systems are internally complex, the drug dose-efficacy relationships can frequently be expressed by low order input-output multi-dimensional surfaces. This finding not only explains the puzzle of why FSC is effective in drug combination optimization, but also serves as the foundation for the idea that a small number of well-designed experimental tests are adequate to form a reasonable response surface for predicting optimal drug combinations and doses.
In a biological system with multiple factors, experimentally testing all the possible drug combinations can be a very laborious, time consuming and costly process. If the response of a biological system can be described with a smooth function, then we only need to perform a small number of tests in order to build up a reliable model for this input-output relationship. This will then allow the rapid examination of the entire search space. This suggests that to optimize combinations of multiple factors in a bio-complex system, we may start with only a few tests and examine whether the bio-system's response is smooth or not. If so, the optimal combination could be faithfully designed by building up the smooth response surface of the system with relatively few test data points. therefore, are believed to be a more universal and effective solution. The aim of this paper is to reveal the fact that although biological systems are internally complex, the relationships between drug doses and phenotypic system responses often follow relatively simple patterns. Furthermore, these patterns can often be modeled faithfully using second order regression analysis. In order to verify this conclusion, the authors have tested the hypothesis in four different biological systems.
These biological systems were selected 'on purpose' to be different in order to cover a relatively large interest of biological research.
Genotypic personalized medicine (GPM) has been extensively discussed recently. GPM diagnoses and categorizes patients based on their genotypic traits, and then treats them based on targeted strategies. GPM has greatly improved response rates to treatment in cancer patients. Yet, epigenetic stimulation can also independently lead to disease. Therefore, genetic investigations only address part of the problem underlying diseased states. For this reason, developing therapeutic strategies based on phenotypic clues may in fact be a more direct route to evaluating the efficacy of a treatment. However, in order to practice phenotypic personalized medicine (PPM), quantitative efficacy-drug relationships need to be understood a priori. The work presented here demonstrates the fact that a low order drug-cell response surface may well commonly exist in many biological systems, indicating that the FSC approach could be an invaluable route towards PPM optimization.
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Materials
Regression modeling
Regression modeling is done with R © and MATLAB © programming languages.
For a bio-complex system with k drugs, a standard form of the linear regression model is as follows:
where 0 , , and are the intercept, linear, quadratic and bilinear (or interaction) terms 24, 25 .
In this study, a full model with all the coefficients (including intercept, linear, quadratic and interaction terms) in a 2 nd order linear regression model was built for each case.
A stepwise linear regression analysis was done in R programming to remove those statistically non-significant regression terms to form a cleaner final regression model. Fitted values and experimentally observed values are plotted side-by-side to evaluate the fitness of the regression model. Residual plot was generated to evaluate whether the regression model is biased for any particular fitted values. Cook Distance plot was generated to tell possible outliers in the experiment, if any. Finally, a series of transformation (log/square-root/square transformation) on the system readout was made to increase the fitting efficiency (P-value) of the regression model.
Data sets
Three datasets were selected in this study based on previously published literature 10, 13, 15 . In all these three cases, the FSC technique was applied to identify optimized drug cocktails to tackle different biological questions. This paper aimed to study why the FSC technique could be implemented so effectively to optimize drug combinations, so we selected to only analyze data sets that were generated using the FSC drug cocktail search practice. The data set in the antiangiogenesis study was generated by the authors in a separate experiment to validate the findings from the study of the first three data sets. and BEZ235 was from Chemdea LLC (Ridgewood, USA). Anti-vimentin monoclonal mouse antibody (clone V9) was purchased from Dako (Glostrup, Denmark) and anti-HMG1 antibody was purchased from Santa Cruz Biotechnology (Heidelberg, Germany). Avastin® was purchsaed from Genentech (San Francisco, CA, USA). RAPTA-C was synthesized and purified based on previous publication 26 .
Drugs acquisition for anti-angiogenesis study
Cell culture and maintenance for anti-angiogenesis study
Immortalized human vascular endothelial cells (ECRF24) were cultured in cell culture medium containing 50% DMEM and 50% RPMI 1640 supplemented with addition of 1% antibiotics (Life Technologies, Carlsbad, California, USA).
Cell viability assay for anti-angiogenesis study
Cells were seeded at density of 2.5 x 10 3 cells/well on a 96-well culture plate. Cells were allowed for 72 h incubation time with drug combinations. Drugs were premixed in culture medium. Cell viability was calculated using the CellTiter-Glo luminescent cell viability assay (Promega, Madison, WI, USA).
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